Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Offers Gengraf Patients Transition Monitoring If Generic Is Pulled

Executive Summary

Novartis will offer blood level monitoring for transplant patients switching from Abbott's Gengraf to other cyclosporine products if the company's motion to have Gengraf removed from the market is granted

You may also be interested in...

Abbott/SangStat May Launch Oral Solution Gengraf To Replace SangCya

SangStat and Abbott are considering launching Abbott's generic cyclosporine oral solution Gengraf following the July 10 recall of SangStat's cyclosporine SangCya, the companies said.

SangStat/Abbott SangCya Co-Promotion Provides Entry To Managed Care

A Sangstat co-promotion agreement with Abbott for its SangCya oral cyclosporine products will provide the company with an experienced partner in the managed care and hospital marketing areas.

FDA Elimination Of Neoral "Microemulsion" Designation Disputed By Novartis

FDA's elimination of "microemulsion" dosage forms is unlawful, Novartis contended in a Feb. 11 lawsuit challenging FDA's approval of SangStat's generic version of Neoral (cyclosporine).

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts